Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrin polymorphisms as risk factors for thrombosis.

P F Bray1

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. pfb@welch.jhu.edu

Thrombosis and Haemostasis
|December 22, 1999
PubMed
Summary

Investigating integrin polymorphisms for thrombosis risk is emerging. Large genetic studies and clinical trials are needed to confirm these genetic variations as true thrombosis risks and explore pharmacogenetics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D ELECTRICAL IMPEDANCE TOMOGRAPHY RECONSTRUCTIONS FROM SIMULATED ELECTRODE DATA USING DIRECT INVERSION t<sup>exp</sup> AND CALDERÓN METHODS.

Inverse problems and imaging (Springfield, Mo.)·2022
Same author

The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y<sub>12</sub> inhibition.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Protease receptor antagonism to target blood platelet therapies.

Clinical pharmacology and therapeutics·2015
Same author

MicroRNAs in platelet production and activation.

Journal of thrombosis and haemostasis : JTH·2013
Same author

The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project.

Journal of thrombosis and haemostasis : JTH·2010
Same author

VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA.

Journal of thrombosis and haemostasis : JTH·2009

Area of Science:

  • Genetics and Thrombosis Research
  • Molecular Biology and Disease Mechanisms

Background:

  • Integrin polymorphisms are being explored as potential genetic risk factors for thrombosis.
  • Current understanding is limited, with ongoing controversies regarding their clinical significance.

Purpose of the Study:

  • To highlight the need for rigorous research into integrin polymorphisms and thrombosis risk.
  • To emphasize the importance of pharmacogenetics in understanding treatment responses.

Main Methods:

  • The abstract discusses the need for large, prospective, genetic epidemiologic studies.
  • It also calls for large clinical trials incorporating patient genotyping.
  • In vitro studies are suggested to elucidate functional consequences.

Main Results:

Related Experiment Videos

  • The current evidence base is insufficient to definitively link integrin polymorphisms to thrombosis risk.
  • Further research is required to resolve existing controversies.

Conclusions:

  • Well-designed genetic epidemiologic studies and clinical trials are essential.
  • Pharmacogenetic analysis in clinical trials is crucial for correlating genetic factors with treatment response.
  • In vitro functional studies will provide a basis for future patient interventions.